Advertisement
Anesthesiology and Pulmonary Medicine
Subscribe to Anesthesiology and Pulmonary Medicine
View Sample

FREE Email Newsletter

Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer

March 11, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

PARIS and TARRYTOWN, N.Y., March 10, 2011 /- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY ) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) today announced results from the Phase III VITAL trial evaluating the investigational agent aflibercept (VEGF Trap) for the second-line treatment...

Simple blood test detects early emphysema in smokers before symptoms appear

March 10, 2011 8:33 pm | by EurekAlert | News | Comments

(New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College) During a regular annual physical exam, blood is usually drawn to check the health of a person's heart, kidneys and liver. Now, researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical...

Exercise Performance in Children and Young Adults with Single Ventricle Heart Disease Improves with Use of Drug for Erectile Dysfunction

March 10, 2011 7:33 am | by Bio-Medicine.Org | News | Comments

PHILADELPHIA, March 10, 2011 /PRNewswire-USNewswire/ -- Sildenafil, a drug used to treat erectile dysfunction and pulmonary hypertension, has another possible use -- helping children and young adults with congenital heart disease to better tolerate exercise. Sildenafil significantly...

Advertisement

University of Wisconsin Carbone Cancer Center to Acquire ViewRay Radiation Therapy System

March 9, 2011 7:33 am | by Bio-Medicine.Org | News | Comments

CLEVELAND, March 9, 2011 /- The University of Wisconsin Carbone Cancer Center (UWCCC) in Madison, Wisconsin, will soon become one of the first oncology research centers to acquire a radiotherapy system from ViewRay™, Inc., a privately held medical device company. ViewRay's new...

Hospira Announces U.S. Approval of Generic Docetaxel

March 9, 2011 6:34 am | by Bio-Medicine.Org | News | Comments

LAKE FOREST, Ill., March 9, 2011 /- Hospira, Inc. (NYSE: HSP ), the world leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval of docetaxel. The medication is a generic version of Sanofi-Aventis's Taxotere®, and Hospira...

Critical Need Exists to Address Health Conditions That Put Patients at Highest Risk for Deep-Vein Thrombosis and Pulmonary Embolism

March 9, 2011 6:34 am | by Bio-Medicine.Org | News | Comments

NEW YORK, March 9, 2011 /- As part of the eighth annual DVT (deep-vein thrombosis) Awareness Month, the Coalition to Prevent DVT is focusing on the importance of DVT and its risk factors among patients with co-morbid conditions – including but not limited to cancer, heart or...

CareFusion Launches Compact Ventilator to Enhance Home-Based Patient Mobility

March 8, 2011 6:34 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, March 8, 2011 /- CareFusion (NYSE: CFN ), a leading, global medical device company, today introduced a portable ventilator for adults and children who require mechanical ventilation at home. (Photo:   http://photos.prnewswire.com/prnh/20110308/LA60768 ) The CareFusion...

March of Dimes provides $2.4 million in new funding for preterm birth research

March 7, 2011 8:34 pm | by EurekAlert | News | Comments

(March of Dimes Foundation) The work of five researchers will be supported for the next three years by new March of Dimes Prematurity Research Initiative grants. The nearly $2.4 million in new grants is being given out by the March of Dimes to support scientific efforts to predict and...

Advertisement

Reportlinker Adds Neuroprotection - Drugs, Markets and Companies

March 7, 2011 9:34 am | by Bio-Medicine.Org | News | Comments

NEW YORK, March 7, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: Neuroprotection - Drugs, Markets and Companies http://www.reportlinker.com/p0203546/Neuroprotection---Drugs-Markets-and-Companies.html SummaryThis report describes the...

CareFusion Appoints Carlos M. Nunez, M.D. as Chief Medical Officer

March 7, 2011 7:33 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, March 7, 2011 /- CareFusion Corporation (NYSE: CFN ), a global, medical technology company, announced today the appointment of Carlos M. Nunez, M.D. as its chief medical officer (CMO). Dr. Nunez, 45, is an anesthesiologist, intensivist and hospitalist as well as an experienced...

Hold your breath: Air pollution plays role in cardiac, metabolic diseases

March 7, 2011 5:33 am | by EurekAlert | News | Comments

(Michigan State University) To explore one of the most critical health/environment intersections -- how the very air we breathe can cause heart disease and diabetes and contribute to the problems of obesity -- Michigan State University has been named a Clean Air Research Center by the...

Rehabilitation within a day of knee replacement pays off

March 6, 2011 5:33 pm | by EurekAlert | News | Comments

(SAGE Publications) Starting rehabilitation sooner following knee arthroplasty surgery could pay dividends -- for both patients and hospitals. Commencing physical therapy within 24 hours of surgery can improve pain, range of joint motion and muscle strength as well as cut hospital stays,...

Avoid risking children's health during home energy retrofits, renovations, experts urge

March 6, 2011 8:34 am | by EurekAlert | News | Comments

(Canadian Environmental Law Association) Home energy retrofits and renovations help fight climate change and can create healthier homes but greater training and caution during the process are needed to avoid the release of asbestos, volatile organic compounds, IQ-lowering lead dust and...

Advertisement

Beaumont First in State to Perform Robotic Heart Procedure for Atrial Fibrillation

March 4, 2011 8:33 am | by Bio-Medicine.Org | News | Comments

ROYAL OAK, Mich., March 4, 2011 /- Doctors at Beaumont Hospital, Troy have performed Michigan's first minimally invasive robotic procedure to correct atrial fibrillation, a prevalent and growing heart rhythm disorder. The new robotic maze procedure is an alternative to open-heart surgery....

Surgeon General, AACR Leaders Urge Increased Investment in Research to Tackle America's Tobacco Epidemic

March 4, 2011 6:33 am | by AACR | News | Comments

WASHINGTON, D.C. - Stemming the tide of tobacco-related deaths and suffering and promoting public health will require renewed control efforts and further research to better understand initiation, addiction and the countless harmful effects of tobacco. These points were emphasized by U.S....

Masimo to Present at the Roth Growth Stock Conference

March 3, 2011 6:35 am | by Bio-Medicine.Org | News | Comments

IRVINE, Calif., March 3, 2011 /- Masimo (Nasdaq: MASI ) today announced that its management is scheduled to present at the Roth 23rd Annual Growth Stock Conference at the Ritz-Carlton in Laguna Niguel, Calif. on Tuesday, March 15, 2011, at 9:00 a.m. P.T.  A live audiocast of the...

Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTAâ„¢

March 3, 2011 4:37 am | by Bio-Medicine.Org | News | Comments

CHAPEL HILL, N.C., March 3, 2011 /- Cempra Pharmaceuticals today announced the appointment of David Oldach, M.D. as vice president, clinical research as well as announcing an expansion of its clinical development team to manage the company's leading clinical programs, solithromycin and...

Insmed Announces European Medicines Agency Acceptance of Its Pediatric Investigation Plan for ARIKACEâ„¢ in the Cystic Fibrosis Pseudomonas Indication

March 3, 2011 4:36 am | by Bio-Medicine.Org | News | Comments

RICHMOND, Va., March 3, 2011 /- Insmed Incorporated (Nasdaq: INSM ), a biopharmaceutical company, announced today that the Pediatric Committee of the European Medicines Agency (EMA) has issued a positive opinion on the Company's Pediatric Investigation Plan (PIP) for ARIKACE™...

Ventus Medical Receives CE Mark for Provent® Sleep Apnea Therapy

March 3, 2011 4:36 am | by Bio-Medicine.Org | News | Comments

BELMONT, Calif., March 3, 2011 /- Ventus Medical, Inc. a privately-held medical device company dedicated to providing novel products to treat sleep-disordered breathing, today announced that it has received CE Mark for its Provent® Sleep Apnea Therapy. (Photo:  ...

Dehaier Medical to Report Fourth Quarter and Full-Year 2010 Financial Results on March 7

March 3, 2011 4:36 am | by Bio-Medicine.Org | News | Comments

BEIJING, March 3, 2011 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (Nasdaq: DHRM ) ("Dehaier" or the "Company"), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that it will...

Ikaria® to Present at 31st Annual Cowen and Company Healthcare Conference

March 2, 2011 6:35 am | by Bio-Medicine.Org | News | Comments

CLINTON, N.J., March 2, 2011 /- Ikaria, Inc. today announced that its Chairman and CEO, Daniel Tasse, will present at the 31st Annual Cowen and Company Healthcare Conference on Wednesday, March 9, 2011 at 8:30 a.m. EST.  The conference will be held March 7-9 at the Boston Marriott...

N30 Pharmaceuticals to Present S-Nitrosoglutathione Reductase Inhibitor Preclinical Safety Data at 2011 Society of Toxicology 50th Anniversary Meeting

March 2, 2011 1:34 am | by Bio-Medicine.Org | News | Comments

BOULDER, Colo., March 2, 2011 /- N30 Pharmaceuticals, LLC (N30 Pharma) today announced it will present data at the 2011 Annual Meeting of the Society of Toxicology in Washington, D.C. on Monday, March 7, 2011. The data describe the preclinical safety evaluation of small molecule...

An Easier Way to Breathe Better - ICAP Ocean Tomo Announces an Advanced Medical Inhaler Design

March 1, 2011 9:34 am | by Bio-Medicine.Org | News | Comments

CHICAGO, March 1, 2011 /- Developed by inventor John Vito and represented by ICAP Ocean Tomo , the assets available for auction in this lot disclose an advanced medical inhaler design that is both more accurate and more convenient for the user. (Logo:  ...

UPDATE: FDA Approves New Drug to Treat Chronic Obstructive Pulmonary Disease

March 1, 2011 9:34 am | by Bio-Medicine.Org | News | Comments

SILVER SPRING, Md., March 1, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration approved roflumilast, a pill taken daily to decrease the frequency of flare-ups (exacerbations) or worsening of symptoms from severe chronic obstructive pulmonary disease (COPD). (Logo:...

Insmed Shareholders Approve Conversion of Series B Conditional Convertible Preferred Stock and Reverse Stock Split

March 1, 2011 6:35 am | by Bio-Medicine.Org | News | Comments

RICHMOND, Va., March 1, 2011 /- Insmed Incorporated (Nasdaq: INSM ), a biopharmaceutical company, announced today that Insmed's shareholders approved the proposal relating to the conversion of Insmed's Series B Conditional Convertible Preferred Stock (Series B Preferred Stock) into...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading